NOUS-PEV: is a vector-based personalised vaccine, expressing 60 nAgs and consists of priming with a nonhuman Great Ape Adenoviral vector (GAd20), cphase Ib trial of NOUS-PEV in combination with pembrolizumab in treatment-naïve patients with metastatic melanoma (NCT04990479) [74].PROSTVAC-VF: A Phase II Randomised, Double Blind, Controlled Study to Evaluate the Safety and Efficacy of PROSTVAC®-VF/TRICOMTM in Combination with GM-CSF in Patients with Androgen-Independent Adenocarcinoma of the Prostate (NCT00081120). This evidence concerns the gene CSF2 and metastatic melanoma.